KREJČÍ, Pavel, Kateřina PEJCHALOVÁ and William R. WILCOX. Simple, mammalian cell-based assay for identification of inhibitors of the ErkMAP kinase pathway. Investigational New Drugs. 2007, vol. 25, No 4, p. 391-395. ISSN 0167-6997. Available from: https://dx.doi.org/10.1007/s10637-007-9054-7.
Other formats:   BibTeX LaTeX RIS
Basic information
Original name Simple, mammalian cell-based assay for identification of inhibitors of the ErkMAP kinase pathway.
Authors KREJČÍ, Pavel (203 Czech Republic, guarantor, belonging to the institution), Kateřina PEJCHALOVÁ (203 Czech Republic, belonging to the institution) and William R. WILCOX (840 United States of America).
Edition Investigational New Drugs, 2007, 0167-6997.
Other information
Original language English
Type of outcome Article in a journal
Field of Study 30105 Physiology
Country of publisher Netherlands
Confidentiality degree is not subject to a state or trade secret
Impact factor Impact factor: 2.806
RIV identification code RIV/00216224:14310/07:00067364
Organization unit Faculty of Science
Doi http://dx.doi.org/10.1007/s10637-007-9054-7
UT WoS 000247275600013
Keywords in English Erk; inhibitor; FGFR3; growth arrest; screening; library
Tags rivok, ZR
Changed by Changed by: prof. Ing. Petr Dvořák, CSc., učo 47260. Changed: 29/4/2014 09:37.
Abstract
The Erk MAP kinase pathway contributes to tumor development and thus represents an important therapeutic target. Several inhibitors of the Erk pathway are presently being evaluated in clinical trials for cancer, but show limited efficiency thus warranting discovery of more potent inhibitors. We have developed a novel mammalian cell-based assay that should facilitate the identification of such compounds by screening molecular libraries. In rat chondrosarcoma (RCS) cells, treatment with fibroblast growth factor 2 (FGF2) leads to sustained activation of the Erk pathway, resulting in growth arrest with more than an 80% cell count difference between control and FGF2-treated cells after 72 h of treatment. The extent of both Erk activation and the growth arrest can be precisely modulated by the FGF2 dose. We also demonstrate that FGF2-mediated activation of the Erk pathway is robust and has only a limited sensitivity to the available MEK inhibitors. The assay is rapid, sensitive and easily adapted to high throughput screening. A major advantage of this system is exclusion of toxic compounds as false-positive hits, given the nature of the RCS response to inhibition of the Erk pathway, i.e. growth.
Links
MSM0021622430, plan (intention)Name: Funkční a molekulární charakteristiky nádorových a normálních kmenových buněk - identifikace cílů pro nová terapeutika a terapeutické strategie
Investor: Ministry of Education, Youth and Sports of the CR, Functional and molecular characteristics of cancer and normal stem cells - identification of targets for novel therapeutics and therapeutic strategies
PrintDisplayed: 26/4/2024 16:57